• Aithal GP, Day CP, Kesteven PJ, Daly AK. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717719.
  • Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King C, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Zhang KQ, Berg RL, Burmester JK. 2008. CYP4F2 genetic variant alters required warfarin dose. Blood (in press).
  • D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. 2005. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645649.
  • Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seilfried E, Müller CR, Wienker TF, Oldenburg J. 2005. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94:773779.
  • Hodge AE, Altman RB, Klein TE. 2007. The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge. Clin Pharmacol Ther 81:2124.
  • Kamali F. 2006. Genetic influences on the response to warfarin. Curr Opin Hematol 13:357361.
  • Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. 2001. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 1:167170.
  • Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. 2004. Identification of the gene for vitamin K epoxide reductase. Nature 427:541544.
  • Nei M. 2007. The new mutation theory of phenotypic evolution. Proc Natl Acad Sci USA 104:1223512242.
  • Owen RP, Klein TE, Altman RB. 2007. The Education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB). Clin Pharmacol Ther 82:472475.
  • Rettie AE, Tai G. 2006. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv 6:223227.
  • Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH. 2006. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol 62:617620.
  • Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:22852293.
  • Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J. 2004. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537541.
  • Vogel F. 1959. Moderne Probleme der Humangenetik. Ergeb Inn Med Kinderheilkd 12:52125.